Chemotherapy Dosing for Cancer

This trial explores new methods to adjust chemotherapy doses for cancer patients with the Duffy-null blood type. In the first phase, researchers will develop a dosing algorithm. In the second phase, they will test its effectiveness in helping patients with this blood type better tolerate chemotherapy. Ideal participants are individuals of Middle Eastern or African descent with newly diagnosed solid organ cancer who have not yet undergone chemotherapy. As a Phase 1 and Phase 2 trial, this research aims to understand how the treatment works and measure its effectiveness, offering participants an opportunity to contribute to groundbreaking advancements in cancer care.

Studies have shown that chemotherapy can be challenging, often causing side effects for many patients. For example, 86% of patients with advanced breast cancer reported significant side effects from their treatment, often leading to dose reductions. Researchers are exploring new ways to manage chemotherapy doses for this reason.

Research also shows that using lower doses of chemotherapy can lead to fewer side effects and a better quality of life, without reducing treatment effectiveness. Adjusting the chemotherapy dose aims to balance manageable side effects with effective cancer treatment.

In this trial, one experimental treatment involves adjusting chemotherapy doses using a special method. Previous patients demonstrated that these adjustments can make the treatment easier to handle, resulting in fewer unwanted side effects and a better experience during treatment.

Researchers are excited about this trial because it explores new ways to personalize chemotherapy dosing for cancer patients based on their Duffy-null blood type. Unlike traditional chemotherapy, which often uses a one-size-fits-all approach guided by CTCAE criteria, this trial uses a specialized algorithm to adjust doses specifically for patients with a positive Duffy-null phenotype. This personalized approach aims to optimize treatment effectiveness while minimizing side effects, potentially leading to better outcomes for patients.

This trial will compare two approaches to chemotherapy dosing. In one arm, patients with a positive Duffy-null blood test will receive standard care chemotherapy with dose adjustments according to an algorithm developed in phase 1 of this study. In the other arm, patients with a negative Duffy-null blood test will receive standard care chemotherapy with delays or modifications based on standard CTCAE grading. Studies have shown that adjusting chemotherapy doses to fit individual patient needs can be effective. One method involves using lower doses of several drugs, which can lessen side effects while maintaining efficacy. Research indicates that low-dose chemotherapy can be as effective as standard doses. Specifically, patients receiving reduced-dose treatments had similar times without cancer progression compared to those on standard doses. This suggests that customizing chemotherapy doses might provide a good balance between treatment effectiveness and quality of life for patients.⁶⁷⁸⁹¹⁰